melanocortin receptor agonist peptide
Is Melanotan II legal?
Answer
Melanotan II is not authorised or registered in any of the 10 registers read.
Each row is what that country's own register said on the date shown. Not legal advice.
| Country | Status | Products on the register | Register | Read |
|---|---|---|---|---|
| United States | Not on the register | - | Regulator FDA | 2026-10-03 |
| European Union | Not on the register | - | Regulator EMA | 2026-08-31 |
| United Kingdom | Not on the register | - | Regulator MHRA | 2026-09-03 |
| Canada | Not on the register | - | Regulator Health Canada | 2026-09-03 |
| Australia | Status unknown | - | TGA | Not read yet |
| Switzerland | Not on the register | - | Regulator Swissmedic | 2026-09-03 |
| Brazil | Not on the register | - | Regulator ANVISA | 2026-09-03 |
| Serbia | Not on the register | - | Regulator ALIMS | 2026-09-03 |
| Singapore | Not on the register | - | Regulator HSA | 2026-09-03 |
| Turkey | Not on the register | - | Regulator TITCK | 2026-09-03 |
A country not listed has no register read yet; see the world map. EU decisions also apply in Iceland, Liechtenstein and Norway.
FDA COMPOUNDING LIST (503A)
Melanotan II is on FDA's 503A bulk-substances list (nominated for compounding, withdrawn by the nominator).
Compounded drugs containing Melanotan II may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities. Published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.
Regulator FDA list, read 2026-10-03. Not legal advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.